Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CRES101
Therapeutic Area : Rare Diseases and Disorders
Study Phase : IND Enabling
Sponsor : Bioasis
Deal Size : Undisclosed
Deal Type : Acquisition
Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets
Details : Under the terms of the agreement, the Company purchased all right, title and interest in the intellectual property owned by the Sellers related to their epidermal growth factor (EGF) platform, including CRES101.
Brand Name : CRES101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 16, 2022
Lead Product(s) : CRES101
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : IND Enabling
Sponsor : Bioasis
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?